

**OPTIMA HEALTH COMMUNITY CARE  
AND  
OPTIMA FAMILY CARE  
(MEDICAID)**

**PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\***

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **Incomplete forms will delay the authorization process.**

**Drug Requested:** Alecensa® (alectinib)

**DRUG INFORMATION:** Complete information below or authorization process will be delayed.

**Drug Form/Strength/Quantity per Day:** \_\_\_\_\_

**Dosing Schedule:** \_\_\_\_\_ **Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_ **ICD Code, if applicable:** \_\_\_\_\_

**CLINICAL CRITERIA:** To receive a **six (6) month approval** for this drug, **ALL** appropriate boxes below **must** be checked to qualify or authorization process will be delayed.

**Does member meet the following criteria?**

- Is medication being prescribed by an oncologist?  Yes  No
- Is member 18 years of age or older?  Yes  No
- Diagnosis of anaplastic lymphoma kinase (ALK) – positive metastatic non-small cell lung cancer?  
 Yes  No
- Diagnosis confirmed by FDA approved genetic test?  Yes  No
- Has member had an intolerance or progression of disease while on crizotinib (Xalkori™)?  
 Yes  No
- Will member have LFTs (every two weeks for the first two months of therapy) and CPK (every two weeks for the first month of therapy)?  Yes  No
- Is dose equal to or greater than 300mg (2x150mg) orally twice daily?  Yes  No

(Package insert states this is the **minimum effective dosage**; however, clinical practice and greater use may yield exceptions, if dosage is lower, please explain rationale below)

**MEDICAL NECESSITY:** Provide clinical evidence/chart notes/documentation that support the use of the requested medication; attach to this request. If not included, authorization process will be delayed.

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

(Continued on next page; signature **MUST** be attached to this request.)

(Signature page **MUST** be attached to this request.)

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Office Contact Name:** \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

**DEA OR NPI #:** \_\_\_\_\_

**REVISED/UPDATED:** 12/23/2017; 8/15/2018